StockNews.com Initiates Coverage on Aeterna Zentaris (NASDAQ:AEZS)

Equities researchers at StockNews.com initiated coverage on shares of Aeterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) in a research report issued to clients and investors on Friday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Aeterna Zentaris Price Performance

Shares of AEZS stock opened at $5.85 on Friday. The firm has a market capitalization of $10.47 million, a price-to-earnings ratio of -0.39 and a beta of 1.55. The business has a fifty day moving average of $6.77 and a 200 day moving average of $7.46. Aeterna Zentaris has a 1 year low of $3.96 and a 1 year high of $12.80.

Aeterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) last issued its earnings results on Tuesday, May 14th. The biopharmaceutical company reported ($4.74) earnings per share (EPS) for the quarter. Aeterna Zentaris had a negative return on equity of 83.45% and a negative net margin of 760.32%.

About Aeterna Zentaris

Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis.